Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

A Protein E-PilA Fusion Protein Shows Vaccine Potential against Nontypeable Haemophilus influenzae in Mice and Chinchillas.

Ysebaert C, Denoël P, Weynants V, Bakaletz LO, Novotny LA, Godfroid F, Hermand P.

Infect Immun. 2019 Jul 23;87(8). pii: e00345-19. doi: 10.1128/IAI.00345-19. Print 2019 Aug.

2.

Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations.

Mayhew D, Devos N, Lambert C, Brown JR, Clarke SC, Kim VL, Magid-Slav M, Miller BE, Ostridge KK, Patel R, Sathe G, Simola DF, Staples KJ, Sung R, Tal-Singer R, Tuck AC, Van Horn S, Weynants V, Williams NP, Devaster JM, Wilkinson TMA; AERIS Study Group.

Thorax. 2018 May;73(5):422-430. doi: 10.1136/thoraxjnl-2017-210408. Epub 2018 Jan 31.

3.

Interleukin-22 protects against non-typeable Haemophilus influenzae infection: alteration during chronic obstructive pulmonary disease.

Sharan R, Perez-Cruz M, Kervoaze G, Gosset P, Weynants V, Godfroid F, Hermand P, Trottein F, Pichavant M, Gosset P.

Mucosal Immunol. 2017 Jan;10(1):139-149. doi: 10.1038/mi.2016.40. Epub 2016 May 4.

PMID:
27143304
4.

Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins.

Bielecka MK, Devos N, Gilbert M, Hung MC, Weynants V, Heckels JE, Christodoulides M.

Infect Immun. 2015 Feb;83(2):730-42. doi: 10.1128/IAI.01815-14. Epub 2014 Dec 1.

5.

Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens.

Williams JN, Weynants V, Poolman JT, Heckels JE, Christodoulides M.

Vaccine. 2014 Mar 5;32(11):1280-6. doi: 10.1016/j.vaccine.2013.12.070. Epub 2014 Jan 30.

PMID:
24486354
6.

Evaluation of truncated NhhA protein as a candidate meningococcal vaccine antigen.

Peak IR, Srikhanta YN, Weynants VE, Feron C, Poolman JT, Jennings MP.

PLoS One. 2013 Sep 6;8(9):e72003. doi: 10.1371/journal.pone.0072003. eCollection 2013.

7.

Meningococcal omp85 in detergent-extracted outer membrane vesicle vaccines induces high levels of non-functional antibodies in mice.

Wedege E, Lie K, Bolstad K, Weynants VE, Halstensen A, Herstad TK, Kreutzberger J, Nome L, Naess LM, Aase A.

Scand J Immunol. 2013 Jun;77(6):452-9. doi: 10.1111/sji.12051.

8.

ZnuD, a potential candidate for a simple and universal Neisseria meningitidis vaccine.

Hubert K, Devos N, Mordhorst I, Tans C, Baudoux G, Feron C, Goraj K, Tommassen J, Vogel U, Poolman JT, Weynants V.

Infect Immun. 2013 Jun;81(6):1915-27. doi: 10.1128/IAI.01312-12. Epub 2013 Mar 18.

9.

Neisseria meningitidis serogroup B lipooligosaccharide genotyping reveals high prevalence of L2 strains in Spain and unexpected relationship with factor H-binding protein expression.

Devos N, Tans C, Momin P, Plisnier M, Weynants V, Feron C, Poolman JT.

Microbes Infect. 2012 Sep;14(11):979-88. doi: 10.1016/j.micinf.2012.04.005. Epub 2012 Apr 20.

PMID:
22565133
10.

Measurement of functional anti-meningococcal serogroup a activity using strain 3125 as the target strain for serum bactericidal assay.

Poolman JT, De Vleeschauwer I, Durant N, Devos N, Feron C, Lestrate P, Weynants V, Boutriau D.

Clin Vaccine Immunol. 2011 Jul;18(7):1108-17. doi: 10.1128/CVI.00549-10. Epub 2011 May 18.

11.

Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults.

Bonvehí P, Boutriau D, Casellas J, Weynants V, Feron C, Poolman J.

Clin Vaccine Immunol. 2010 Sep;17(9):1460-6. doi: 10.1128/CVI.00129-10. Epub 2010 Jul 21.

12.

An outer membrane receptor of Neisseria meningitidis involved in zinc acquisition with vaccine potential.

Stork M, Bos MP, Jongerius I, de Kok N, Schilders I, Weynants VE, Poolman JT, Tommassen J.

PLoS Pathog. 2010 Jul 1;6:e1000969. doi: 10.1371/journal.ppat.1000969.

13.

Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response.

Weynants V, Denoël P, Devos N, Janssens D, Feron C, Goraj K, Momin P, Monnom D, Tans C, Vandercammen A, Wauters F, Poolman JT.

Infect Immun. 2009 May;77(5):2084-93. doi: 10.1128/IAI.01108-08. Epub 2009 Mar 16.

14.

Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay.

Findlow J, Holland A, Andrews N, Weynants V, Sotolongo F, Balmer P, Poolman J, Borrow R.

Clin Vaccine Immunol. 2007 Nov;14(11):1451-7. Epub 2007 Sep 19.

15.

Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis.

Weynants VE, Feron CM, Goraj KK, Bos MP, Denoël PA, Verlant VG, Tommassen J, Peak IR, Judd RC, Jennings MP, Poolman JT.

Infect Immun. 2007 Nov;75(11):5434-42. Epub 2007 Jul 30.

16.

Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents.

Boutriau D, Poolman J, Borrow R, Findlow J, Domingo JD, Puig-Barbera J, Baldó JM, Planelles V, Jubert A, Colomer J, Gil A, Levie K, Kervyn AD, Weynants V, Dominguez F, Barberá R, Sotolongo F.

Clin Vaccine Immunol. 2007 Jan;14(1):65-73. Epub 2006 Oct 25.

17.

Shielding of immunogenic domains in Neisseria meningitidis FrpB (FetA) by the major variable region.

Kortekaas J, Pettersson A, van der Biezen J, Weynants VE, van der Ley P, Poolman J, Bos MP, Tommassen J.

Vaccine. 2007 Jan 2;25(1):72-84. Epub 2006 Jul 28.

PMID:
16914236
18.

Immunogenicity and structural characterisation of an in vitro folded meningococcal siderophore receptor (FrpB, FetA).

Kortekaas J, Müller SA, Ringler P, Gregorini M, Weynants VE, Rutten L, Bos MP, Tommassen J.

Microbes Infect. 2006 Jul;8(8):2145-53. Epub 2006 May 24.

PMID:
16797200
19.

Vaccine potential of the Neisseria meningitidis lactoferrin-binding proteins LbpA and LbpB.

Pettersson A, Kortekaas J, Weynants VE, Voet P, Poolman JT, Bos MP, Tommassen J.

Vaccine. 2006 Apr 24;24(17):3545-57. Epub 2006 Feb 20.

PMID:
16517031
20.

Function of neisserial outer membrane phospholipase a in autolysis and assessment of its vaccine potential.

Bos MP, Tefsen B, Voet P, Weynants V, van Putten JP, Tommassen J.

Infect Immun. 2005 Apr;73(4):2222-31.

21.

Early detection of Borrelia burgdorferi sensu lato infection in Balb/c mice by co-feeding Ixodes ricinus ticks.

Hua CM, Cheminade Y, Perret JL, Weynants V, Lobet Y, Gern L.

Int J Med Microbiol. 2003 Dec;293(6):421-6.

PMID:
14760973
22.

Analysis of the antigen-specific IFN-gamma producing T-cell subsets in cattle experimentally infected with Mycobacterium bovis.

Walravens K, Wellemans V, Weynants V, Boelaert F, deBergeyck V, Letesson JJ, Huygen K, Godfroid J.

Vet Immunol Immunopathol. 2002 Jan 1;84(1-2):29-41.

PMID:
11825596
23.

Stable expression of biologically active recombinant bovine interleukin-4 in Trypanosoma brucei.

Furger A, Jungi TW, Salomone JY, Weynants V, Roditi I.

FEBS Lett. 2001 Nov 9;508(1):90-4.

24.

Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.

Pal U, Montgomery RR, Lusitani D, Voet P, Weynants V, Malawista SE, Lobet Y, Fikrig E.

J Immunol. 2001 Jun 15;166(12):7398-403.

25.

Antigenic conservation of an immunodominant invariable region of the VlsE lipoprotein among European pathogenic genospecies of Borrelia burgdorferi SL.

Liang FT, Aberer E, Cinco M, Gern L, Hu CM, Lobet YN, Ruscio M, Voet PE Jr, Weynants VE, Philipp MT.

J Infect Dis. 2000 Nov;182(5):1455-62. Epub 2000 Oct 9.

PMID:
11023468
26.

Effects of bovine herpesvirus type 1 infection in calves with maternal antibodies on immune response and virus latency.

Lemaire M, Weynants V, Godfroid J, Schynts F, Meyer G, Letesson JJ, Thiry E.

J Clin Microbiol. 2000 May;38(5):1885-94.

27.

Antigenic properties of peptidic mimics for epitopes of the lipopolysaccharide from Brucella.

De Bolle X, Laurent T, Tibor A, Godfroid F, Weynants V, Letesson JJ, Mertens P.

J Mol Biol. 1999 Nov 19;294(1):181-91.

PMID:
10556037
28.

T-cell responses and the influence of dendritic cells in cattle.

Howard CJ, Collins RA, Sopp P, Brooke GP, Kwong LS, Parsons KR, Weynants V, Letesson JJ, Bembridge GP.

Adv Vet Med. 1999;41:275-88. Review. No abstract available.

PMID:
9890022
29.

Quantitative assessment by flow cytometry of T-lymphocytes producing antigen-specific gamma-interferon in Brucella immune cattle.

Weynants V, Walravens K, Didembourg C, Flanagan P, Godfroid J, Letesson JJ.

Vet Immunol Immunopathol. 1998 Dec 11;66(3-4):309-20.

PMID:
9880107
30.

Production and characterisation of monoclonal antibodies specific for bovine interleukin-4.

Weynants V, Gilson D, Furger A, Collins RA, Mertens P, De Bolle X, Heussler VT, Roditi I, Howard CJ, Dobbelaere AE, Letesson JJ.

Vet Immunol Immunopathol. 1998 Nov 24;66(2):99-112.

PMID:
9860184
31.

O-Polysaccharide epitopic heterogeneity at the surface of Brucella spp. studied by enzyme-linked immunosorbent assay and flow cytometry.

Cloeckaert A, Weynants V, Godfroid J, Verger JM, Grayon M, Zygmunt MS.

Clin Diagn Lab Immunol. 1998 Nov;5(6):862-70.

32.

Identification of the perosamine synthetase gene of Brucella melitensis 16M and involvement of lipopolysaccharide O side chain in Brucella survival in mice and in macrophages.

Godfroid F, Taminiau B, Danese I, Denoel P, Tibor A, Weynants V, Cloeckaert A, Godfroid J, Letesson JJ.

Infect Immun. 1998 Nov;66(11):5485-93.

33.

Immune response of calves experimentally infected with non-cell-culture-passaged bovine respiratory syncytial virus.

Knott I, Weynants V, Walravens K, van der Poel WH, Kramps JA, Letesson JJ.

Arch Virol. 1998;143(6):1119-28.

PMID:
9687869
34.

Survival of a bacterioferritin deletion mutant of Brucella melitensis 16M in human monocyte-derived macrophages.

Denoel PA, Crawford RM, Zygmunt MS, Tibor A, Weynants VE, Godfroid F, Hoover DL, Letesson JJ.

Infect Immun. 1997 Oct;65(10):4337-40.

35.

Humoral immune responses of Brucella-infected cattle, sheep, and goats to eight purified recombinant Brucella proteins in an indirect enzyme-linked immunosorbent assay.

Letesson JJ, Tibor A, van Eynde G, Wansard V, Weynants V, Denoel P, Saman E.

Clin Diagn Lab Immunol. 1997 Sep;4(5):556-64.

36.

Identification of the major T-cell antigens present in the Brucella melitensis B115 protein preparation, Brucellergene OCB.

Denoel PA, Vo TK, Weynants VE, Tibor A, Gilson D, Zygmunt MS, Limet JN, Letesson JJ.

J Med Microbiol. 1997 Sep;46(9):801-6.

PMID:
9291893
37.

Characterization of smooth lipopolysaccharides and O polysaccharides of Brucella species by competition binding assays with monoclonal antibodies.

Weynants V, Gilson D, Cloeckaert A, Tibor A, Denoel PA, Godfroid F, Limet JN, Letesson JJ.

Infect Immun. 1997 May;65(5):1939-43.

38.

Characterization, occurrence, and molecular cloning of a 39-kilodalton Brucella abortus cytoplasmic protein immunodominant in cattle.

Denoel PA, Vo TK, Tibor A, Weynants VE, Trunde JM, Dubray G, Limet JN, Letesson JJ.

Infect Immun. 1997 Feb;65(2):495-502.

39.

Assessment of the cell-mediated immunity in cattle infection after bovine herpesvirus 4 infection, using an in vitro antigen-specific interferon-gamma assay.

Godfroid J, Czaplicki G, Kerkhofs P, Weynants V, Wellemans G, Thiry E, Letesson JJ.

Vet Microbiol. 1996 Nov;53(1-2):133-41.

PMID:
9011005
40.

Detection of Yersinia enterocolitica serogroup O:3 by a PCR method.

Weynants V, Jadot V, Denoel PA, Tibor A, Letesson JJ.

J Clin Microbiol. 1996 May;34(5):1224-7.

41.
42.

Infection of cattle with Yersinia enterocolitica O:9 a cause of the false positive serological reactions in bovine brucellosis diagnostic tests.

Weynants V, Tibor A, Denoel PA, Saegerman C, Godfroid J, Thiange P, Letesson JJ.

Vet Microbiol. 1996 Jan;48(1-2):101-12.

PMID:
8701566
43.
44.

Cloning and sequencing of the bacterioferritin gene of Brucella melitensis 16M strain.

Denoel PA, Zygmunt MS, Weynants V, Tibor A, Lichtfouse B, Briffeuil P, Limet JN, Letesson JJ.

FEBS Lett. 1995 Mar 20;361(2-3):238-42.

45.

Specific bovine brucellosis diagnosis based on in vitro antigen-specific gamma interferon production.

Weynants V, Godfroid J, Limbourg B, Saegerman C, Letesson JJ.

J Clin Microbiol. 1995 Mar;33(3):706-12.

46.

Molecular cloning, nucleotide sequence, and occurrence of a 16.5-kilodalton outer membrane protein of Brucella abortus with similarity to pal lipoproteins.

Tibor A, Weynants V, Denoel P, Lichtfouse B, De Bolle X, Saman E, Limet JN, Letesson JJ.

Infect Immun. 1994 Sep;62(9):3633-9.

Supplemental Content

Loading ...
Support Center